REPLIMUNE GROUP, INC. Share-based Payment Arrangement, Expense
REPLIMUNE GROUP, INC. (REPL) reported Share-based Payment Arrangement, Expense of $7.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-14
- REPLIMUNE GROUP, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $7.67M, a 12.42% decline year-over-year.
- REPLIMUNE GROUP, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $8.13M, a 1.87% decline year-over-year.
- REPLIMUNE GROUP, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $7.05M, a 18.43% decline year-over-year.
- REPLIMUNE GROUP, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $8.34M, a 3.61% decline year-over-year.
- REPLIMUNE GROUP, INC. share-based payment arrangement, expense for fiscal 2026 was $32.27M, a 7.91% decline from fiscal 2025.
- REPLIMUNE GROUP, INC. share-based payment arrangement, expense for fiscal 2025 was $35.04M, a 2.69% increase from fiscal 2024.
- REPLIMUNE GROUP, INC. share-based payment arrangement, expense for fiscal 2024 was $34.13M.
- REPLIMUNE GROUP, INC. share-based payment arrangement, expense for fiscal 2020 was $7.74M, a 183.55% increase from fiscal 2019.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.67M 10-Q · filed 2026-08-14 | $15.80M derived: sum of 2 quarters · filed 2026-08-14 | $22.85M derived: sum of 3 quarters · filed 2026-08-14 | $31.18M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $8.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $15.17M derived: sum of 2 quarters · filed 2026-06-29 | $23.51M derived: sum of 3 quarters · filed 2026-06-29 | $32.27M 10-K · filed 2026-06-29 |
| 2025-12-31 | $7.05M 10-Q · filed 2026-02-03 | $15.38M derived: sum of 2 quarters · filed 2026-02-03 | $24.15M 10-Q · filed 2026-02-03 | $32.43M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | $8.34M 10-Q · filed 2025-11-06 | $17.10M 10-Q · filed 2025-11-06 | $25.38M derived: sum of 3 quarters · filed 2026-08-14 | $34.02M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $8.76M 10-Q · filed 2026-08-14 | $17.04M derived: sum of 2 quarters · filed 2026-08-14 | $25.68M derived: sum of 3 quarters · filed 2026-08-14 | $34.33M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $8.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $16.92M derived: sum of 2 quarters · filed 2026-06-29 | $25.57M derived: sum of 3 quarters · filed 2026-06-29 | $35.04M 10-K · filed 2026-06-29 |
| 2024-12-31 | $8.64M 10-Q · filed 2026-02-03 | $17.29M derived: sum of 2 quarters · filed 2026-02-03 | $26.76M 10-Q · filed 2026-02-03 | $34.69M derived: sum of 4 quarters · filed 2026-02-03 |
| 2024-09-30 | $8.65M 10-Q · filed 2025-11-06 | $18.13M 10-Q · filed 2025-11-06 | $26.05M derived: sum of 3 quarters · filed 2025-11-06 | $34.29M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $9.47M 10-Q · filed 2025-08-07 | $17.40M derived: sum of 2 quarters · filed 2025-08-07 | $25.64M derived: sum of 3 quarters · filed 2025-08-07 | $34.75M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $7.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22 | $16.16M derived: sum of 2 quarters · filed 2025-05-22 | $25.28M derived: sum of 3 quarters · filed 2025-05-22 | $34.13M 10-K · filed 2025-05-22 |
| 2023-12-31 | $8.24M 10-Q · filed 2025-02-12 | $17.36M derived: sum of 2 quarters · filed 2025-02-12 | $26.20M 10-Q · filed 2025-02-12 | |
| 2023-09-30 | $9.11M 10-Q · filed 2024-11-12 | $17.96M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $8.85M 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $7.02M 10-Q · filed 2024-02-08 | $14.02M derived: sum of 2 quarters · filed 2024-02-08 | $21.21M 10-Q · filed 2024-02-08 | |
| 2022-09-30 | $6.99M 10-Q · filed 2023-11-07 | $14.19M 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $7.19M 10-Q · filed 2023-08-03 | |||
| 2021-12-31 | $5.92M 10-Q · filed 2023-02-09 | $12.23M derived: sum of 2 quarters · filed 2023-02-09 | $18.48M 10-Q · filed 2023-02-09 | |
| 2021-09-30 | $6.31M 10-Q · filed 2022-11-03 | $12.56M 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $6.25M 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $3.05M 10-Q · filed 2022-02-03 | $5.85M derived: sum of 2 quarters · filed 2022-02-03 | $8.32M 10-Q · filed 2022-02-03 | |
| 2020-09-30 | $2.80M 10-Q · filed 2021-11-04 | $5.27M 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $2.47M 10-Q · filed 2021-08-06 | |||
| 2020-03-31 | $7.74M 10-K · filed 2020-06-03 | |||
| 2019-06-30 | $1.81M 10-Q · filed 2019-08-14 | $2.72M derived: sum of 2 quarters · filed 2020-06-03 | $3.60M derived: sum of 3 quarters · filed 2020-06-03 | $4.34M derived: sum of 4 quarters · filed 2020-06-03 |
| 2019-03-31 | $907.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | $1.79M derived: sum of 2 quarters · filed 2020-06-03 | $2.53M derived: sum of 3 quarters · filed 2020-06-03 | $2.73M 10-K · filed 2020-06-03 |
| 2018-12-31 | $881.00K 10-Q · filed 2019-02-14 | $1.62M derived: sum of 2 quarters · filed 2019-02-14 | $1.82M 10-Q · filed 2019-02-14 | $2.20M derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-09-30 | $742.00K 10-Q · filed 2018-11-14 | $943.00K 10-Q · filed 2018-11-14 | $1.32M derived: sum of 3 quarters · filed 2020-06-03 | $1.58M derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-06-30 | $225.00K 10-Q · filed 2019-08-14 | $579.00K derived: sum of 2 quarters · filed 2020-06-03 | $836.00K derived: sum of 3 quarters · filed 2020-06-03 | $992.00K derived: sum of 4 quarters · filed 2020-06-03 |
| 2018-03-31 | $354.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | $611.00K derived: sum of 2 quarters · filed 2020-06-03 | $767.00K derived: sum of 3 quarters · filed 2020-06-03 | $812.00K 10-K · filed 2020-06-03 |
| 2017-12-31 | $257.00K 10-Q · filed 2019-02-14 | $413.00K derived: sum of 2 quarters · filed 2019-02-14 | $458.00K 10-Q · filed 2019-02-14 | |
| 2017-09-30 | $156.00K 10-Q · filed 2018-11-14 | $201.00K 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $45.00K 10-Q · filed 2018-08-30 | |||
| 2017-03-31 | $208.00K 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |